David Gorenstein's Biography

David Gorenstein, Associate Dean for Research/Founder AM, The University of Texas Health Science Center

David G. Gorenstein, Ph.D., is Associate Dean for Research and interim Chair of the Department of NanoMedicine and Biomedical Engineering at the University of Texas Health Sciences Center at Houston. He is also Deputy Director of the Institute of Molecular Medicine and James T. Willerson Distinguished Chair and Director, Center for Proteomics and Systems Biology. He also serves as Director of the Gulf Coast Consortium in Magnetic Resonance, a shared facility that includes UTMB, Rice, Baylor College of Medicine, U. Houston, UT HSC Houston and UT M.D. Anderson Cancer Center. He is Director of Translational Technologies for the UT HSC Houston/MD Anderson Cancer Center CTSA – the Center for Clinical and Translational Research. He has over 40 years experience in structural biology, drug design, nucleic acid and protein chemistry with over 260 publications. He received his SB degree at MIT and his PhD at Harvard University, both in Chemistry. He currently has a major program in proteomics and nanomedicine for both diagnostics and therapeutics in both infectious diseases and cancer. He has received a number of awards, including Guggenheim and Fulbright fellowships and election as Fellow to the AAAS. Dr. Gorenstein holds over 36 patents (awarded and pending) on next-generation aptamer, bead-based combinatorial library selection technologies and is Founder of AM Biotechnologies, a spin-off company in Houston, which has licensed these technologies from his laboratory. Dr. Gorenstein is PI on a NICHD National Children’s Study Center for Proteomics and Project Leader on both an NHLBI Proteomics Center and an NIAID Clinical Proteomics Center in Infectious Diseases. He is PI for the new Texas Center for Cancer Nanomedicine, one of the NCI Nanomedicine Centers.